T. Li

Modified Expansion-Floating Craniotomy for Refractory Intracranial Hypertension: A Technical Review and Case Series

Qiumeng Li, T. Li, Zhong Liu, Yunpeng Dong et autres

OBJECTIVE: Decompressive craniectomy (DC) relieves refractory intracranial hypertension but produces a cranial defect that mandates secondary cranioplasty and carries substantial morbidity. Bone-flap-preserving alternatives exist but are constrained by limited decompressive volume or the need for a second repositioning operation. We describe a …

cn (code pays fourni par la source)

A simple and aesthetically pleasing floating craniotomy: How I do it

T. Li, Qiumeng Li, Ji Xia, Yunpeng Dong et autres

BACKGROUND: Decompressive craniectomy and subsequent cranioplasty are associated with significant morbidity (Kurland et al. Neurocrit Care 23:292-304, 2015). Bone flap-preserving techniques, including floating and hinged craniotomies, offer effective intracranial pressure (ICP) control (Mohan et al. Acta Neurochir (Wien) 163(5):1415-1422, 2021), although the …

cn (code pays fourni par la source)

A Causal and interpretable machine learning framework for postcranioplasty risk prediction and surgical decision support

Wenbo Li, Bao Wang, T. Li, Y. Ma et autres

Cranioplasty is associated with a substantial burden of postoperative complications. In this multicenter study, we developed a machine learning-based clinical decision-support tool to predict the risk of postoperative complications following cranioplasty. A set of nine features was selected for model development. Among …

cn (code pays fourni par la source)

Giant Cervical Pseudomeningocele Following Traumatic Brachial Plexus Traction Injury: A Case Report

Jun Chen, Chun Zhou, Lunshan Xu, T. Li

cn (code pays fourni par la source)

Development and Internal-External Validation of Interpretable Machine Learning Models to Predict the Risk of Postoperative Complications after Cranioplasty: A Multicenter, Cohort Study

Wen Li, Bao Wang, T. Li, Y. Ma et autres

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects

Sreeneeranj Kasichayanula, Xuejun Liu, W. C. Shyu, W. Zhang et autres

AIMS: Dapagliflozin increases urinary glucose excretion by selectively inhibiting renal sodium-glucose transporter 2, an insulin-independent mechanism of action that may be complementary to that of other oral antidiabetes drugs. The current studies assessed the potential for pharmacokinetic (PK) interaction between dapagliflozin and …

de, us, se (code pays fourni par la source)

The efficacy and safety of abatacept in patients with non–life‐threatening manifestations of systemic lupus erythematosus: Results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trial

Joan T. Merrill, Rubén Burgos‐Vargas, René Westhovens, Andrew Chalmers et autres

OBJECTIVE: To evaluate abatacept therapy in patients with non-life-threatening systemic lupus erythematosus (SLE) and polyarthritis, discoid lesions, or pleuritis and/or pericarditis. METHODS: In a 12-month, multicenter, exploratory, phase IIb randomized, double-blind, placebo-controlled trial, SLE patients with polyarthritis, discoid lesions, or pleuritis and/or …

us, mx, be, ca, gb, kr, de, au (code pays fourni par la source)

Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept

Jason C. Cole, T. Li, Phoebe Lin, Ross Maclean et autres

OBJECTIVES: Quality of life (QoL) improvement is important to demonstrate in RA clinical trials, but can be abstract. More meaningful measures of QoL include medical expenditure and job loss, aspects that have marked importance for RA patients, physicians and society. We re-examined …

us, se (code pays fourni par la source)

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

Michael Schiff, M. Keiserman, C. Codding, S Songcharoen et autres

us, br, ar, Afrique du Sud, mx, fr (code pays fourni par la source)

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial

Michael E. Weinblatt, M. Schiff, Allan L. Goldman, J.M. Kremer et autres

us (code pays fourni par la source)

A clinically meaningful difference was generated for a performance measure of recovery from hip fracture

William Hawkes, Grant R. Williams, S. Zimmerman, Pablo Lapuerta et autres

us (code pays fourni par la source)